Volume : 13, Issue : 09, September – 2026
Title:
DEVELOPMENT AND CHARACTERIZATION OF POLMACOXIB FLOATING TABLETS
Authors :
P.Sravani*, Balu Akshay, Nandigama Mounika , Sadia Anees , Venna Sreeja
Abstract :
The present study was carried out to develop and characterise floating tablets of Polmacoxib, a selective cyclooxygenase-2 (COX-2) inhibitor NSAID used in the treatment of osteoarthritis. The objective was to enhance gastric residence time, provide sustained drug release, and improve therapeutic efficacy through a gastroretentive drug delivery system. Floating tablets were prepared by the direct compression method using Polmacoxib, Ethyl Cellulose, Eudragit RS100, Microcrystalline Cellulose (MCC), Sodium Bicarbonate, Talc, and Magnesium Stearate. Four formulations (F1–F4) were developed with varying concentrations of polymers. Preformulation studies, including organoleptic evaluation, solubility studies, UV spectroscopic analysis, and FTIR compatibility studies, were performed. FTIR results confirmed the absence of drug–excipient interactions. The prepared formulations exhibited satisfactory flow properties and were further evaluated for physical characteristics, floating lag time, buoyancy, drug content, and in-vitro drug release. Formulation 1: Lag time is 54 sec; Drug Release is 94.68% Formulation 2: Lag time is 62 sec; Drug Release is 93.26% Formulation 3: Lag time is 42 sec: Drug Release is 93.39% Formulation 4: Lag time is 48 sec; Drug Release is 95.52% 3 Among all formulations, F3 showed the best performance with a floating lag time of 42 seconds, buoyancy exceeding 8 hours, and a cumulative drug release of 96.39% within 8 hours. Stability studies conducted for 90 days indicated no significant changes in the physical and chemical properties of the optimised formulation. The results demonstrated that Polmacoxib floating tablets can be successfully formulated by direct compression, and formulation F3 was identified as the optimised formulation due to its excellent floating behaviour, sustained drug release, and stability. Thus, the developed floating tablet system represents a promising approach for improving the oral delivery and therapeutic effectiveness of Polmacoxib.
Keywords: Polmacoxib, Synthetic Polymers, FTIR studies, Direct compression technique, In vitro drug release studies.
Cite This Article:
Please cite this article in press P.Sravani et al Development And Characterization Of Polmacoxib Floating Tablets.,. Indo Am. J. P. Sci, 2026; 13(09).
REFERENCES:
1. Streubel A, Siepmann J, Bodmeier R. Gastroretentive drug delivery systems. Expert Opin Drug Deliv. 2006;3(2):217-233.
2. Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F. Gastroretentive dosage forms: overview and special case of Helicobacter pylori. J Control Release. 2006;111(1-2):1-18.
3. Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable gastroretentive dosage forms. J Control Release. 2003;90(2):143-162.
4. Garg R, Gupta GD. Progress in controlled gastroretentive delivery systems. Trop J Pharm Res. 2008;7(3):1055-1066.
5. Arora S, Ali J, Ahuja A, Khar RK, Baboota S. Floating drug delivery systems: a review. AAPS PharmSciTech. 2005;6(3):E372-E390.
6. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release. 2000;63(3):235-259.
7. Streubel A, Siepmann J, Bodmeier R. Floating microparticles based on low-density foam powder. Int J Pharm. 2002;241(2):279-292.
8. Chawla G, Gupta P, Koradia V, Bansal AK. Gastroretention: a means to address regional variability in intestinal drug absorption. Pharm Technol. 2003;27(7):50-68.
9. Rouge N, Buri P, Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int J Pharm. 1996;136(1-2):117-139.
10. Moës AJ. Gastroretentive dosage forms. Crit Rev Ther Drug Carrier Syst. 1993;10(2):143-195.
11. Hoffman A. Pharmacodynamic aspects of sustained release preparations. Adv Drug Deliv Rev. 1998;33(3):185-199.
12. Lopes CM, Bettencourt C, Rossi A, Buttini F, Barata P. Overview on gastroretentive drug delivery systems for improving drug bioavailability. Int J Pharm. 2016;510(1):144-158.
13. Amaral, M.H., Lobo, J.M., Ferreira, D.C., 2001. Effect of hydroxypropyl methylcellulose and hydrogenated castor oil on naproxen release from sustained-release tablets. AAPS Pharm. Sci. Tech. 2, E6.
14. Andrews, G.P., Laverty, T.P., Jones, D.S., 2009. Mucoadhesive polymeric platforms for controlled drug delivery. Eur. J. Pharm. Biopharm. 71, 505-518.
15. Atyabi, F., Sharma, H.L., Mohammad, H.A.H., Fell, J.T., 1996a. Controlled drug release from coated floating ion exchange resin beads. J. Control. Rel. 42, 25-28.
16. Atyabi, F., Sharma, H.L., Mohammad, H.A.H., Fell, J.T., 1996b. In vivo evaluation of a novel gastric retentive formulation based on ion exchange resins. J. Control. Rel. 42, 105-113.
17. Babu, V.B., Khar, R.K., 1990. In vitro and in vivo studies of sustained-release floating dosage forms containing salbutamol sulfate. Pharmazie 45, 268-270.